← Back to Clinical Trials
Recruiting NCT04306432

NCT04306432 Cognitive Function After Radiation Therapy for Primary Brain Tumours

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04306432
Status Recruiting
Phase
Sponsor University of Aarhus
Condition Primary Brain Tumour
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2019-01-03
Primary Completion 2034-03-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type OBSERVATIONAL
Interventions
Cognitive tests and Patient Reported Outcomes

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2019-01-03 with a primary completion date of 2034-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will assess cognitive function in patients with a primary brain tumour treated with radiation therapy (RT) to generate radio-sensitivity and volume effect parameters for the development of cognitive dysfunction. All types of brain tumours apart from glioblastoma will be included.

Eligibility Criteria

Inclusion Criteria: * 18 years or older and Danish speaking. * Performance status WHO 0-2 * Capable of cooperating on testing * Tumour histology (WHO 2016 classification) of the following types: anaplastic astrocytoma (IDH mutant), diffuse astrocytoma (IDH-mutant), gemistocytic astrocytoma (IDH mutant), diffuse astrocytoma (NOS), oligodendroglioma, meningioma, medulloblastoma (NOS), pituitary adenoma, other brain tumours including skull base sarcomas Exclusion Criteria: * Glioblastoma * Performance status 3-4 (Karnofsky Performances of 60 or less)

Contact & Investigator

Central Contact

Morten Høyer, MD

✉ morthoey@rm.dk

📞 +45 2328 2823

Principal Investigator

Lene Haldbo-Classen, M.D

PRINCIPAL INVESTIGATOR

Aarhus University Hospital

Frequently Asked Questions

Who can join the NCT04306432 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Primary Brain Tumour. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04306432 currently recruiting?

Yes, NCT04306432 is actively recruiting participants. Contact the research team at morthoey@rm.dk for enrollment information.

Where is the NCT04306432 trial being conducted?

This trial is being conducted at Copenhagen, Denmark, Aarhus, Denmark, Aarhus, Denmark, Aalborg, Denmark and 1 additional location.

Who is sponsoring the NCT04306432 clinical trial?

NCT04306432 is sponsored by University of Aarhus. The principal investigator is Lene Haldbo-Classen, M.D at Aarhus University Hospital. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology